Rybelsus Dosage

Generic name: SEMAGLUTIDE 3mg
Dosage form: oral tablet
Drug class: GLP-1 Agonists (Incretin Mimetics)

Medically reviewed by Drugs.com. Last updated on Dec 9, 2024.

Overview of RYBELSUS Formulations

•

There are two RYBELSUS formulations (i.e., formulation R1 and formulation R2) with different recommended dosages. Refer to recommendations on how to switch from one formulation to another formulation.

o: RYBELSUS (formulation R1) includes strengths 3 mg, 7 mg and 14 mg.
o: RYBELSUS (formulation R2) includes strengths 1.5 mg, 4 mg and 9 mg.

•

These formulations are not substitutable on a mg per mg basis.

•

Use either RYBELSUS formulation R1or formulation R2; do not use both formulations at the same time.

•

Do not take more than one tablet per day.

Important Administration Instructions

•: Take RYBELSUS on an empty stomach in the morning with water (up to 4 ounces of water). Do not take RYBELSUS with other liquids besides water.
•: After taking RYBELSUS, wait at least 30 minutes before eating food, drinking beverages or taking other oral medications.
•: Swallow tablets whole. Do not split crush or chew.
•: If a dose is missed, skip the missed dose and take the next dose the following day.

Recommended Starting, Escalation and Maintenance Dosage of RYBELSUS Formulations R1 and R2

RYBELSUS (formulation R1)

RYBELSUS (formulation R1) includes the following strengths: 3 mg, 7 mg and 14 mg.

Recommend the following RYBELSUS (formulation R1) dosage to reduce the risk of gastrointestinal adverse reactions:

•

Starting Dosage (Initiation Phase) (Days 1 to 30): The recommended starting dosage is 3 mg orally once daily (this dosage is not effective for glycemic control).

•

Escalation and Maintenance Dosage (Days 31 and beyond):

o

Days 31 to 60: Increase the dosage to 7 mg orally once daily.

o

On Day 61 or thereafter, if:

▪: No additional glycemic control is needed, maintain the dosage at 7 mg orally once daily.
▪: Additional glycemic control is needed, increase the dosage to 14 mg orally once daily.

RYBELSUS (formulation R2)

RYBELSUS (formulation R2) includes the following strengths: 1.5 mg, 4 mg and 9 mg.

Recommend the following RYBELSUS (formulation R2) dosage to reduce the risk of gastrointestinal adverse reactions:

•

Starting Dosage (Initiation Phase) (Days 1 through 30): The recommended starting dosage is 1.5 mg orally once daily (this dosage is not effective for glycemic control).

•

Escalation and Maintenance Dosage (Days 31 and beyond):

o

Days 31 to 60: Increase the dosage to 4 mg orally once daily.

o

On Day 61 or thereafter, if:

▪: No additional glycemic control is needed maintain the dosage at 4 mg orally once daily.
▪: Additional glycemic control is needed increase the dosage to 9 mg orally once daily.

Switching Between RYBELSUS (Formulations R1 or R2) or from OZEMPIC to RYBELSUS

Switching Between RYBELSUS Formulations

•: Do not switch between RYBELSUS formulations during the initiation phase (Days 1-30).
•: After 30 days of RYBELSUS treatment (after the initiation phase), patients may switch between RYBELSUS formulations (see Table 1).
•: When switching between the formulations, initiate the other RYBELSUS formulation the day after discontinuing the previous RYBELSUS formulation.
: Table 1. Switching Between Escalation or Maintenance Dosage of RYBELSUS Formulations

RYBELSUS (formulation R1) *	RYBELSUS (formulation R2) *
7 mg orally once daily	4 mg orally once daily
14 mg orally once daily	9 mg orally once daily

: *Discontinue this formulation and initiate the alternate formulation the day after

Switching from OZEMPIC to RYBELSUS (formulation R1) or RYBELSUS (formulation R2)

Switching from OZEMPIC to RYBELSUS (formulation R1)

•: One week after discontinuing 0.5 mg of subcutaneous OZEMPIC, start 7 mg or 14 mg of RYBELSUS (formulation R1) orally once daily.
•: Switching recommendations for patients taking Ozempic 0.25 mg, 1 mg or 2 mg subcutaneously once weekly to RYBELSUS (formulation R1) are not available.

Switching from OZEMPIC to RYBELSUS (formulation R2)

•: One week after discontinuing 0.5 mg of subcutaneous OZEMPIC, start 4 mg or 9 mg of RYBELSUS (formulation R2) orally once daily.
•: Switching recommendations for patients taking Ozempic 0.25 mg, 1 mg or 2 mg subcutaneously once weekly to RYBELSUS (formulation R2) are not available.